# Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)

Study · id `cardio:ct-nct05887817` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05887817](<https://clinicaltrials.gov/study/NCT05887817>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05887817

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05887817. Randomized; quadruple masking; primary purpose treatment. Start 2023-09-07 (actual); primary completion 2025-02-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05887817, source copy `cardio:ctgov-nct05887817-2024-02-07`, retrieved 2026-10-26)
- Started: 2023-09-07 (actual) (ClinicalTrials.gov record NCT05887817, source copy `cardio:ctgov-nct05887817-2024-02-07`, retrieved 2026-10-26)
- Primary completion: 2025-02-28 (anticipated) (ClinicalTrials.gov record NCT05887817, source copy `cardio:ctgov-nct05887817-2024-02-07`, retrieved 2026-10-26)
- Completion: 2026-07-31 (anticipated) (ClinicalTrials.gov record NCT05887817, source copy `cardio:ctgov-nct05887817-2024-02-07`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT05887817, source copy `cardio:ctgov-nct05887817-2024-02-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05887817-2024-02-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
- Acronym: FIVE-STAR
- Condition: Type 2 Diabetes
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Finerenone
- Intervention (Drug): Placebo
- Lead sponsor: Saga University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Finerenone (`cardio:finerenone`)
- Registry intervention is a member of this class by a sourced record link: Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- Registry lists this organization as the lead sponsor: Saga University (`cardio:org-saga-university`)

## Provenance

Content hash: e9e2701ecf2d24fd29b63e027b7d947128b4dead3fe4c8d69e603c091c4b4898
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
